No one said it was a new thing, but this isn't R&D like you are describing. This is a completed pre-clinical program with phase 1 data already available.Many companies license out their production. nothing new about that.
Many companies run very few production runs at their "R&D facilities" and then license the production out when its stable. Its normal business procedure. Its extremely rare that a company does it all them self.
Same with R&D, its normal its a collaborative effort. Again nothing new about that.
Tsuji is one of those, Replicel does the same. many does this. Even within the car industry its quite normal to buy into R&D from their suppliers.
I would bet its rather difficult to find a company that DOES NOT license out anything.
If this were a home run profitability wise then Bayer would be holding universal rights and developing it in-house. They clearly see massive potential risk or a lack of profitability to drag it past phase 1 and then license it out.